STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks
Tag
Pharmalot
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
Pharmalot
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
Pharma
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
Pharmalot
STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
Pharmalot
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalot
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more.
Pharma
STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug
Pharma
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial
Pharma
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
Pharmalot
STAT+: Genentech is soliciting research that can be used to blunt pharma reforms in Washington
How a pharma company is soliciting research that can be used to blunt pharma proposed reforms in Washington.